NO985095L - Substituerte indazolderivater og deres anvendelse som inhibitorer fosfodies terase (PDE) type IV og produksjon av tumornekrosefaktor (TNF) - Google Patents

Substituerte indazolderivater og deres anvendelse som inhibitorer fosfodies terase (PDE) type IV og produksjon av tumornekrosefaktor (TNF)

Info

Publication number
NO985095L
NO985095L NO985095A NO985095A NO985095L NO 985095 L NO985095 L NO 985095L NO 985095 A NO985095 A NO 985095A NO 985095 A NO985095 A NO 985095A NO 985095 L NO985095 L NO 985095L
Authority
NO
Norway
Prior art keywords
pde
phosphodiesterase
tnf
inhibitors
production
Prior art date
Application number
NO985095A
Other languages
English (en)
Other versions
NO312959B1 (no
NO985095D0 (no
Inventor
Anthony Marfat
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO985095D0 publication Critical patent/NO985095D0/no
Publication of NO985095L publication Critical patent/NO985095L/no
Publication of NO312959B1 publication Critical patent/NO312959B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
NO19985095A 1996-05-03 1998-11-02 Substituerte indazolderivater, anvendelse derav samt farmasöytisk preparat NO312959B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1686196P 1996-05-03 1996-05-03
PCT/IB1997/000323 WO1997042174A1 (en) 1996-05-03 1997-04-01 Substituted indazole derivatives and their use as inhibitors phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf)

Publications (3)

Publication Number Publication Date
NO985095D0 NO985095D0 (no) 1998-11-02
NO985095L true NO985095L (no) 1998-12-29
NO312959B1 NO312959B1 (no) 2002-07-22

Family

ID=21779401

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19985095A NO312959B1 (no) 1996-05-03 1998-11-02 Substituerte indazolderivater, anvendelse derav samt farmasöytisk preparat

Country Status (42)

Country Link
US (2) US6211222B1 (no)
EP (1) EP0912521B1 (no)
JP (1) JP3148254B2 (no)
KR (1) KR100339935B1 (no)
CN (2) CN1112359C (no)
AP (4) AP1147A (no)
AR (1) AR006906A1 (no)
AT (1) ATE292626T1 (no)
AU (1) AU725576B2 (no)
BG (1) BG64211B1 (no)
BR (1) BR9709051A (no)
CA (2) CA2252982C (no)
CO (1) CO4650038A1 (no)
CZ (1) CZ292825B6 (no)
DE (1) DE69732966T2 (no)
DZ (1) DZ2217A1 (no)
EA (1) EA002272B1 (no)
ES (1) ES2238079T3 (no)
GT (1) GT199700043A (no)
HK (1) HK1019443A1 (no)
HN (1) HN1997000046A (no)
HR (1) HRP970227B1 (no)
HU (1) HUP9902459A3 (no)
ID (1) ID16856A (no)
IL (2) IL126547A (no)
IS (1) IS4871A (no)
MA (1) MA24158A1 (no)
MY (1) MY132499A (no)
NO (1) NO312959B1 (no)
NZ (1) NZ332240A (no)
OA (1) OA10904A (no)
PE (1) PE64598A1 (no)
PL (1) PL329836A1 (no)
SK (1) SK148298A3 (no)
TN (1) TNSN97070A1 (no)
TR (1) TR199802202T2 (no)
TW (1) TW449585B (no)
UA (1) UA65536C2 (no)
UY (1) UY24532A1 (no)
WO (1) WO1997042174A1 (no)
YU (1) YU16397A (no)
ZA (1) ZA973804B (no)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP1147A (en) * 1996-05-03 2003-02-25 Pfizer Substituted indazole derivatives and related compounds.
US6005118A (en) * 1996-05-03 1999-12-21 Caron; Stephane Methods of preparing 4-cyano-4 (substituted indazole) cyclohexane-carboxylic acids useful as PDE4 inhibitors
CA2258728C (en) 1996-06-19 2011-09-27 Rhone Poulenc Rorer Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
DK0983249T3 (da) * 1997-05-08 2002-07-08 Pfizer Prod Inc Fremgangsmåder og mellemprodukter til fremstilling af substituerede indazolderivater
CA2309175A1 (en) * 1997-11-04 1999-05-14 Pfizer Products Inc. Therapeutically active compounds based on indazole bioisostere replacement of catechol in pde4 inhibitors
IL126745A (en) * 1997-11-04 2003-09-17 Pfizer Prod Inc Methods of preparing 4-cyano-4- (substituted indazole) cyclohexanecarboxylic acids useful as pde4 inhibitors
JP2001521926A (ja) * 1997-11-04 2001-11-13 ファイザー・プロダクツ・インク 治療上活性の化合物におけるカテコールのインダゾール生物学的等価物置換
IL132407A0 (en) * 1998-10-21 2001-03-19 Pfizer Prod Inc Method for treating congestive heart failure
JP2000198734A (ja) * 1998-12-30 2000-07-18 Pfizer Inc 胃運動性減弱および関連疾患の治療のための運動性増強薬
JP2003519139A (ja) * 1999-12-23 2003-06-17 アイコス コーポレイション 環状ａｍｐ−特異的ホスホジエステラーゼ阻害剤
US6362213B1 (en) 1999-12-23 2002-03-26 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US7211594B2 (en) * 2000-07-31 2007-05-01 Signal Pharmaceuticals, Llc Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
US6953774B2 (en) 2000-08-11 2005-10-11 Applied Research Systems Ars Holding N.V. Methods of inducing ovulation
ATE526013T1 (de) 2001-12-14 2011-10-15 Merck Serono Sa Verfahren zur herbeiführung einer ovulation über einen nicht-polypeptid-camp-spiegel-modulator
US20040034084A1 (en) * 2002-05-24 2004-02-19 Celgene Corporation Methods for using JNK inhibitors for treating or preventing disease-related wasting
US7196082B2 (en) * 2002-11-08 2007-03-27 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
US20050019366A1 (en) * 2002-12-31 2005-01-27 Zeldis Jerome B. Drug-coated stents and methods of use therefor
DE10318610A1 (de) 2003-04-24 2004-11-11 Elbion Ag 7-Azaindole und deren Verwendung als Therapeutika
US7601847B2 (en) 2004-10-26 2009-10-13 Wyeth Preparation and purification of 4-(indazol-3-yl)phenols
US20070004777A1 (en) * 2005-03-23 2007-01-04 Bhagwat Shripad S Methods for treating or preventing acute myelogenous leukemia
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
BRPI0710636A2 (pt) * 2006-04-21 2011-08-23 Centocor Inc antagonistas de cxcl 31 e o uso dos mesmos para o tratamento de doenças inflamatórias
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2804603A1 (en) 2012-01-10 2014-11-26 President and Fellows of Harvard College Beta-cell replication promoting compounds and methods of their use
KR20200104291A (ko) 2017-11-06 2020-09-03 랩트 테라퓨틱스, 인크. 항암제

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3994890A (en) * 1974-01-31 1976-11-30 Chugai Seiyaku Kabushiki Kaisha 1-Aminoalkyl, 3-phenyl indazoles
JPS5654437A (en) * 1979-10-09 1981-05-14 Konishiroku Photo Ind Co Ltd Direct positive image forming method
GB8707051D0 (en) * 1986-04-15 1987-04-29 Ici America Inc Heterocyclic carboxamides
JP2525286B2 (ja) * 1990-11-26 1996-08-14 日本原子力研究所 超耐熱性炭化ケイ素繊維の製造方法
TW223004B (no) * 1991-11-25 1994-05-01 Sumitomo Chemical Co
US5444038A (en) * 1992-03-09 1995-08-22 Zeneca Limited Arylindazoles and their use as herbicides
PT630367E (pt) * 1992-03-09 2000-10-31 Zeneca Ltd Novos arilindazoles e sua utilizacao como herbicidas
US5552438A (en) * 1992-04-02 1996-09-03 Smithkline Beecham Corporation Compounds useful for treating allergic and inflammatory diseases
US5554620A (en) * 1993-09-14 1996-09-10 Sterling Winthrop Inc. Substituted 6,11-ethano-6,11-dihydrobenzo[b] quinolizinium salts and compositions and methods of use thereof
US5440038A (en) * 1993-12-07 1995-08-08 Miles Inc. Process for the purification of substituted 4-amino-1,2,4-triazine-5-ones
PL319758A1 (en) * 1994-10-20 1997-08-18 Pfizer Bicyclic tetrahydropyrasole pyridines and their application as medicines
KR970707243A (ko) * 1994-10-21 1997-12-01 헤이만, 로버트 엘 금속제품에 대한 내식성 완충 시스템(corrosion resistant buffer system for metal products)
AP1147A (en) * 1996-05-03 2003-02-25 Pfizer Substituted indazole derivatives and related compounds.
DK0983249T3 (da) * 1997-05-08 2002-07-08 Pfizer Prod Inc Fremgangsmåder og mellemprodukter til fremstilling af substituerede indazolderivater

Also Published As

Publication number Publication date
OA10904A (en) 2001-10-11
HN1997000046A (es) 1997-06-26
SK148298A3 (en) 2000-02-14
NO312959B1 (no) 2002-07-22
MY132499A (en) 2007-10-31
AP0102304A0 (en) 1997-11-03
NO985095D0 (no) 1998-11-02
AP1146A (en) 2003-02-25
HRP970227A2 (en) 2000-12-31
EA199800882A1 (ru) 1999-06-24
AP2001002294A0 (en) 2001-12-31
CA2252982A1 (en) 1997-11-13
AR006906A1 (es) 1999-09-29
ZA973804B (en) 1998-11-02
HK1019443A1 (en) 2000-02-11
ID16856A (id) 1997-11-13
KR20000010751A (ko) 2000-02-25
IL152083A0 (en) 2003-05-29
IL126547A0 (en) 1999-08-17
PE64598A1 (es) 1998-10-26
WO1997042174A1 (en) 1997-11-13
HUP9902459A3 (en) 2001-10-29
TW449585B (en) 2001-08-11
CN1422849A (zh) 2003-06-11
DZ2217A1 (fr) 2002-12-03
JP3148254B2 (ja) 2001-03-19
PL329836A1 (en) 1999-04-12
US6127398A (en) 2000-10-03
EA002272B1 (ru) 2002-02-28
AP1147A (en) 2003-02-25
IL126547A (en) 2003-03-12
HUP9902459A2 (hu) 1999-11-29
AU725576B2 (en) 2000-10-12
NZ332240A (en) 2000-07-28
EP0912521B1 (en) 2005-04-06
JPH11508284A (ja) 1999-07-21
DE69732966T2 (de) 2005-09-08
CN1112359C (zh) 2003-06-25
BR9709051A (pt) 1999-08-03
BG64211B1 (bg) 2004-05-31
TNSN97070A1 (fr) 2005-03-15
ATE292626T1 (de) 2005-04-15
HRP970227B1 (en) 2002-06-30
CA2252982C (en) 2002-10-08
MA24158A1 (fr) 1997-12-31
GT199700043A (es) 1998-10-02
TR199802202T2 (xx) 1999-02-22
ES2238079T3 (es) 2005-08-16
BG102946A (en) 1999-11-30
CZ292825B6 (cs) 2003-12-17
AP9700975A0 (en) 1997-07-31
KR100339935B1 (ko) 2002-07-18
DE69732966D1 (de) 2005-05-12
AU1937397A (en) 1997-11-26
AP2001002304A0 (en) 2001-12-31
UY24532A1 (es) 2000-09-29
CN1217714A (zh) 1999-05-26
EP0912521A1 (en) 1999-05-06
CZ349298A3 (cs) 1999-09-15
CO4650038A1 (es) 1998-09-03
US6211222B1 (en) 2001-04-03
YU16397A (sh) 1999-12-27
CA2389918A1 (en) 1997-11-13
IS4871A (is) 1998-10-16
UA65536C2 (en) 2004-04-15

Similar Documents

Publication Publication Date Title
NO985095L (no) Substituerte indazolderivater og deres anvendelse som inhibitorer fosfodies terase (PDE) type IV og produksjon av tumornekrosefaktor (TNF)
NO986103L (no) Substituerte indazol-derivater og deres anvendelse som fosfodiesterase (PDE)type IV - og tumornekrose-faktor (TNF)inhibitorer
NO991048D0 (no) Indazolderivater og deres anvendelse som inhibitorer av fosfodiesterase (PDE) type IV og fremstillingen av tumornekrosefaktor (TNF)
NO20015797D0 (no) Indazolforbindelser og farmasöytiske forbindelser for inhibering av proteinkinaser, og fremgangsmåter til anvendelsederav
DK1475377T3 (da) Indol-derivater og deres anvendelse som inhibitorer for phosphodiesterase 4
DK1000039T3 (da) Substituerede quinazolinderivater og anvendelse deraf som tyrosinkinaseinhibitorer
NO941679D0 (no) Gallesyrederivater, fremgangsmåte for fremstilling og deres anvendelse
HUP0004512A3 (en) 4-aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases
AU2002226911A1 (en) Indol derivative and their use as inhibitors of p38 kinase
DK326989D0 (da) Alminoalkylaminocarbonylaminodiolaminosyrederivater og deres anvendelse som renininhibitorer
DK0950657T3 (da) Substituerede carbazoler, fremgangsmåde til deres fremstilling og deres anvendelse som sPLA2-inhibitorer
NO995036D0 (no) 5,7-disubstituerte 4-aminopyrido[2,3-d]pyrimidinforbindelser og deres anvendelse som adenosinkinaseinhibitorer
EE03745B1 (et) Asendatud 4-bifenüül-4-hüdroksübutaanhappe derivaadid metalloproteaasimaatriksi inhibiitoritena
DK0983249T3 (da) Fremgangsmåder og mellemprodukter til fremstilling af substituerede indazolderivater
NO984624D0 (no) Nye furan-diarylmetyliden-derivater, fremgangsmÕte for deres fremstilling og terapeutiske anvendelser derav
DK0862550T3 (da) Hidtil ukendte carboxylsyrederivater, deres fremstilling og anvendelse

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees